These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38659524)

  • 1. Sociodemographic Disparities in Sodium-Glucose Co-Transporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists Prescription Patterns Among Patients With Poorly Controlled Diabetes.
    Antwi-Amoabeng D; Beutler BD; Ghuman J; Ulanja MB; Ghuman J; Gullapalli N
    Cureus; 2024 Mar; 16(3):e56845. PubMed ID: 38659524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Race and Ethnicity With Prescription of SGLT2 Inhibitors and GLP1 Receptor Agonists Among Patients With Type 2 Diabetes in the Veterans Health Administration System.
    Lamprea-Montealegre JA; Madden E; Tummalapalli SL; Peralta C; Neilands TB; Garcia PK; Muiru A; Karliner L; Shlipak MG; Estrella MM
    JAMA; 2022 Sep; 328(9):861-871. PubMed ID: 36066519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis.
    Kanie T; Mizuno A; Takaoka Y; Suzuki T; Yoneoka D; Nishikawa Y; Tam WWS; Morze J; Rynkiewicz A; Xin Y; Wu O; Providencia R; Kwong JS
    Cochrane Database Syst Rev; 2021 Oct; 10(10):CD013650. PubMed ID: 34693515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. All-cause mortality and cardiovascular outcomes with sodium-glucose Co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes.
    Riley DR; Essa H; Austin P; Preston F; Kargbo I; Ibarburu GH; Ghuman R; Cuthbertson DJ; Lip GYH; Alam U
    Diabetes Obes Metab; 2023 Oct; 25(10):2897-2909. PubMed ID: 37385958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risks of stroke, its subtypes and atrial fibrillation associated with glucagon-like peptide 1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a real-world population-based cohort study in Hong Kong.
    Lui DTW; Tang EHM; Wu T; Au ICH; Lee CH; Woo YC; Tan KCB; Wong CKH
    Cardiovasc Diabetol; 2023 Feb; 22(1):40. PubMed ID: 36829226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. National Trends in Use of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists by Cardiologists and Other Specialties, 2015 to 2020.
    Adhikari R; Jha K; Dardari Z; Heyward J; Blumenthal RS; Eckel RH; Alexander GC; Blaha MJ
    J Am Heart Assoc; 2022 May; 11(9):e023811. PubMed ID: 35475341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and Safety Outcomes With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes: A Real-World Study.
    Edwards K; Li X; Lingvay I
    J Clin Endocrinol Metab; 2023 Mar; 108(4):920-930. PubMed ID: 36268825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comorbidities and neighborhood factors associated with prescription of sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists among medically underserved populations.
    Ogunsanmi DO; Harrison AT; Pakker AR; Kovesdy CP; Bailey JE; Surbhi S
    J Manag Care Spec Pharm; 2023 Jun; 29(6):699-711. PubMed ID: 37276038
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison of Diabetes Medications Used by Adults With Commercial Insurance vs Medicare Advantage, 2016 to 2019.
    McCoy RG; Van Houten HK; Deng Y; Mandic PK; Ross JS; Montori VM; Shah ND
    JAMA Netw Open; 2021 Feb; 4(2):e2035792. PubMed ID: 33523188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in Australia in the era of increased evidence of their cardiovascular benefits (2014-2022).
    Lin J; Pearson SA; Greenfield JR; Park KH; Havard A; Brieger D; Day RO; Falster MO; de Oliveira Costa J
    Eur J Clin Pharmacol; 2023 Sep; 79(9):1239-1248. PubMed ID: 37449993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM).
    Gourdy P; Darmon P; Dievart F; Halimi JM; Guerci B
    Cardiovasc Diabetol; 2023 Apr; 22(1):79. PubMed ID: 37005640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Patients with Coronary Artery Disease.
    Hofer F; Kazem N; Schweitzer R; Hammer A; Jakse F; Koller L; Hengstenberg C; Sulzgruber P; Niessner A
    Cardiovasc Drugs Ther; 2021 Dec; 35(6):1161-1170. PubMed ID: 33666822
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between glucagon-like peptide-1 receptor agonists and biliary-related diseases in patients with type 2 diabetes: A nationwide cohort study.
    Dong YH; Wu JH; Chang CH; Lin JW; Wu LC; Toh S
    Pharmacotherapy; 2022 Jun; 42(6):483-494. PubMed ID: 35508702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta-analysis.
    Mantsiou C; Karagiannis T; Kakotrichi P; Malandris K; Avgerinos I; Liakos A; Tsapas A; Bekiari E
    Diabetes Obes Metab; 2020 Oct; 22(10):1857-1868. PubMed ID: 32476254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disparities in SGLT2 Inhibitor or Glucagon-Like Peptide 1 Receptor Agonist Initiation Among Medicare-Insured Adults With CKD in the United States.
    Zhao JZ; Weinhandl ED; Carlson AM; St Peter WL
    Kidney Med; 2023 Jan; 5(1):100564. PubMed ID: 36593878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study.
    Chan YH; Chao TF; Chen SW; Lee HF; Li PR; Chen WM; Yeh YH; Kuo CT; See LC; Lip GYH
    Cardiovasc Diabetol; 2022 Jun; 21(1):118. PubMed ID: 35765074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium-glucose co-transporter 2 inhibitors & glucagon-like peptide-1 receptor agonists, efficacy & safety in diabetic kidney transplant recipients.
    Mahmoud T; Yagan J; Hasan A; Gheith OA; Mostafa M; Rida S; El-Serwi N; Shaker M; Khalid M
    Clin Transplant; 2023 Dec; 37(12):e15144. PubMed ID: 37755118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. County-level variation in cardioprotective antihyperglycemic prescribing among medicare beneficiaries.
    Hanna J; Nargesi AA; Essien UR; Sangha V; Lin Z; Krumholz HM; Khera R
    Am J Prev Cardiol; 2022 Sep; 11():100370. PubMed ID: 35968531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective Effects of Home T2DM Treatment with Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Co-transporter-2 Inhibitors Against Intensive Care Unit Admission and Mortality in the Acute Phase of the COVID-19 Pandemic: A Retrospective Observational Study in Italy.
    Monda VM; Voci C; Strollo F; Passaro A; Greco S; Monesi M; Bigoni R; Porcellati F; Piani D; Satta E; Gentile S
    Diabetes Ther; 2023 Dec; 14(12):2127-2142. PubMed ID: 37801224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular and mortality outcomes with GLP-1 receptor agonists vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study.
    Krishnan A; Schneider CV; Hadi Y; Mukherjee D; AlShehri B; Alqahtani SA
    Diabetologia; 2024 Mar; 67(3):483-493. PubMed ID: 38117293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.